MedPath

A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
Registration Number
NCT00191984
Lead Sponsor
Eli Lilly and Company
Brief Summary

A non-randomized phase II study to determine the efficacy and safety of the combination of Pemetrexed and Irinotecan every two weeks in metastatic colorectal cancer patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
46
Inclusion Criteria
  • Diagnosis of metastatic colorectal adenocarcinoma that is not amenable to curative therapy.
  • Patient must have at least one unidimensionally measurable lesion.
  • Prior radiation therapy to less than 25% of bone marrow. Radiation must be completed at least 4 weeks prior to study enrollment.
  • Performance status 0 to 2
  • Patient must have received 1 prior course of chemotherapy (Folfox regimen) for metastatic disease
Exclusion Criteria
  • Treatment with any drug within the last 30 days that has not received regulatory approval.
  • Serious systemic disorder (cardiac or pulmonary disease, active infection)
  • Documented brain metastases not amenable to surgery or unstable after radiation
  • Inability or unwillingness to take folic acid or Vitamin B12 supplementation.
  • Presence of fluid retention that can not be controlled by drainage.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Pemetrexed + Irinotecanirinotecan-
Pemetrexed + Irinotecanpemetrexed-
Primary Outcome Measures
NameTimeMethod
Best Overall Tumor Responsebaseline to measured progressive disease (up to 2 years follow-up)

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.

Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.

Secondary Outcome Measures
NameTimeMethod
Duration of Responsetime of response to progressive disease or death (up to 2 years follow-up)

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.

Progression-Free Survival (PFS)baseline to measured progressive disease or death (up to 2 years follow-up)

Defined as the time from study enrollment to the first date of disease progression or death as a result of any cause. PFS was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed.

Time to Treatment Failurebaseline to stopping treatment (up to 2 years follow-up)

Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

Overall Survivalbaseline to date of death from any cause (up to 2 years follow-up)

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.

🇫🇷

Suresnes, France

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
🇫🇷Suresnes, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.